预约演示
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics
2023-05-18
临床3期临床结果
Doubts led SVB Securities analysts to review their estimates on the peak sales potential for sepiapterin.
PTC Therapeutics’ phase 3 clinical trial in the rare inherited disorder phenylketonuria (PKU)sepiapterins primary endpoint. And yet, the design of the study means analysts remain unsure about the strength of PTC’s hand and whether it can rival BioMarin’s Kuvan and live up to its $400 million peak sales forecast.
PTC TherapeuticsPTC study compared sepiapterin to placebo in 98 patients. Sepiapterin, lphenylketonuria (PKU)d to treat PKU by lowering elevated blood phenylalanine (Phe), an amino acid that builds up in people with the disease and can cause intellectual disabBioMarinhe phase 3 trial confirmed sepiapterin can significantly cut Phe levels. What that means for the prospects of the drug candidate is less certain.
While the primary esepiapterin met with a 63% mean blood PSepiapterinn in thKuvann population, "we stillPKUve outstanding questions, and it remains unclear if estimates for this program are achievable,” analysts at SVB Securitintellectual disabilityinvestors.sepiapterin
The trial showed “minimal” improvements in the placebo arm, causing the study to hit its primary endpoint with a p-value of 0.0001. The analysis was limited to patients who had at least a 30% reduction in Phe in the first part of the clinical trial.
The reduction in Phe far exceeds the 29% decline seen in BioMarin’s Kuvan trial, but there are doubts about whether the cross-trial assessment is comparing like with like. Participants in the Kuvan trial had a higher baseline Phe, 843µmol/L in the treatment group, than their counterparts in the sepiapterin study, 646µmol/L. It is possible BioMarin’s smaller decline in Phe reflects its enrollment of sicker patients.
PTC separated out the data on patients with classical PKUBioMarinre form of the disease. The reduction in Phe in the subgroup was 69%, a deep reduction that has question marks hanging over it because of the limitations of the data set. As the SVB Securities analysts note, the randomized portion sepiapterinl included six classical patients,BioMarinir baseline Phe, 761µmol/L, was only a little above that of the overall study population and well below the 1,200µmol/L threshold used to diagnose the severe form of PKU.
“We wonder if the six randomized classical PKU patients in the sepiapterin arm will be sufficient to include this patient group on the label. Moreover, we believe the way Classical patients were defined in the study is rather loose, especially considering their baseline blood Phe levels were not much higher than the overall study population,” the analysts wrote.PKU
The doubts have led the analysts to review their estimates. Presepiapterine SVB Securities team forecast peak sales of $400 million, reflecting their assumption that sepiapterin will penetrate 25% of Kuvan-responsive patients and 25% of non-responders to the BioMarin drug.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。